PharmaTher Launches Personaliz3D Peptides(TM) to Advance Personalized Peptide Care Following Positive FDA Advisory Committee Recommendations

About this update from Pharmather Holdings Ltd

New division will address the limitations of traditional peptide compounding through 3D printing and AI PharmaTher plans to connect patients, physicians and qualified pharmacies through an integrated telemedicine platform Positive PCAC recommendations represent an important potential step toward regulated access to compounded peptides in the United States Toronto, Ontario--(Newsfile Corp. - July 27, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on personalized medicines, announced today the launch of Personaliz3D Peptides™, a new division focused on developing and commercializing personalized peptide products and protocols using 3D printing and artificial intelligence technologies. Patients and healthcare providers are increasingly seeking peptide therapies tailored to individual treatment goals. However, traditional peptide compounding is often limited to fixed doses, injectable or liquid formulations, and fragmented access through separate prescribers, pharmacies and technology providers, with additional variability in quality standards and limited access to verified GMP-compliant manufacturing controls. PharmaTher established Personaliz3D Peptides™ to help address these limitations. The division intends to create an integrated personalized peptide ecosystem that leverages 3D printing and artificial intelligence alongside physician oversight, telemedicine, qualified compounding pharmacies, proprietary formulations, and precise dosing to enable more advanced and individualized treatment design, including alternative delivery formats. Potential formats may include gummies, oral films, tablets, gels, chews, suppositories and patches. The launch follows last week's positive votes by the U.S. Food and Drug Administration's Pharmacy Compounding Advisory Committee ("PCAC"), which recommended that BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax be included on the Section 503A Bulks List. PharmaTher believes the PCAC recommendations represent an important potential step toward establishing a responsible regulatory framework for the development, compounding and clinical evaluation of personalized peptide medicines in the United States. "Patients and healthcare providers should not have to rely on a one-size-fits-all approach when individual treatment needs can differ signif...

View stock analysis, news, and events for Pharmather Holdings Ltd